FR-190997, a nonpeptide bradykinin B2-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys

Najam A. Sharif, Parvaneh Katoli, Daniel Scott, Linya Li, Curtis Kelly, Shouxi Xu, Shahid Husain, Carol Toris, Craig Crosson

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


FR-190997 (8-[2,6-dichloro-3-[N-[(E)-4-(N-methylcarbamoyl) cinnaminoacetyl]-Nmethylamino] benzyloxy]-2-methyl-4- (2-pyridylmethoxy) quinoline), a nonpeptide bradykinin (BK) B2-receptor-selective agonist, represents a novel class of ocular hypotensive agents. FR-190997 exhibited a high affinity for the human cloned B2-receptor (K i = 9.8 nM) and a relatively high potency (EC50 = 155 nM) for mobilizing intracellular Ca2+ ([Ca2+]i) in human ocular cells from nonpigmented ciliary epithelium; trabecular meshwork [h-TM]; ciliary muscle [h-CM] that are involved in regulating intraocular pressure (IOP). Unlike BK, FR-190997 behaved as a partial agonist (E max = 38-80%) in these cells and its [Ca2+]i - mobilizing effects were blocked by the B2-receptor-selective antagonists (HOE-140, Ki = 0.8-7 nM; WIN- 64338, Ki = 157-425 nM). FR-190997 stimulated the production of prostaglandins (PGs) in h-CM and h-TM cells (EC50 = 15-19 nM; Emax = 27-33%); an effect that was reduced by the cyclooxygenase-2 inhibitor bromfenac, and by HOE-140. FR-190997 also induced pro-matrix metalloproteinase (MMP)-1 and MMP-3 release from h-CM cells. FR-190997 significantly lowered IOP (37% [P < 0.001] with 30 μg, 24 h posttopical ocular dosing) in ocular hypertensive eyes of conscious Cynomolgus monkeys. This effect was reduced by bromfenac and completely blocked by a B2-antagonist. FR-190997 primarily stimulated uveoslceral outflow (UVSO) of aqueous humor (2.6 to 3.9-fold above baseline). In conclusion, FR-190997 is a B2-receptor selective partial agonist that activates phospholipase C, mobilizes [Ca2+]; induces PG and pro-MMP production, and that profoundly lowers IOP by promoting UVSO in ocular hypertensive Cynomolgus monkey eyes.

Original languageEnglish (US)
Pages (from-to)211-223
Number of pages13
JournalDrug Development Research
Issue number4
StatePublished - Jun 2014


  • Bradykinin
  • FR-190997
  • Intraocular pressure

ASJC Scopus subject areas

  • Drug Discovery


Dive into the research topics of 'FR-190997, a nonpeptide bradykinin B<sub>2</sub>-receptor partial agonist, is a potent and efficacious intraocular pressure lowering agent in ocular hypertensive cynomolgus monkeys'. Together they form a unique fingerprint.

Cite this